NS34A resistance-associated substitutions in chronic hepatitis C in Upper Egypt and regression of liver fibrosis after direct-acting antiviral therapy

Egyptian Liver Journal

Table 5 LSM before and 72 weeks after SMV/SOF therapy in SVR patients

Baseline liverfibrosis stage	Mean liver stiffnessbefore treatment(baseline) (kPa),mean ± SD	Mean liver stiffness72 weeks aftertreatment (kPa),mean ± SD	P value
F1 (n = 4)	6.4 ± 0.5	5.4 ± 0.9	0.088 ns
F2 (n = 17)	8.5 ± 0.5	6.1 ± 1.3	0.001*
F3 (n = 10)	10.7 ± 0.7	6.9 ± 2	0.001*
F4 (n = 16)	24.9 ± 6.9	20.7 ± 5.6	< 0.05*
Total (n = 47)	15.12 ± 0.54	10.27 ± 0.97	0.001*